Poor Glycemic Control Is a Risk Factor for Triple- Negative Breast Cancer in Patients With Type 2 Diabetes
Recommended Citation
Miller M, Bell M, Holland P, Ibrahim V, Jacobsen G, Swain M. Poor Glycemic Control Is a Risk Factor for Triple- Negative Breast Cancer in Patients With Type 2 Diabetes. Obstet Gynecol 2022; 139(SUPPL 1):93S.
Document Type
Conference Proceeding
Publication Date
5-1-2022
Publication Title
Obstet Gynecol
Keywords
endogenous compound, epidermal growth factor receptor 2, hemoglobin A1c, hormone receptor, adult, breast cancer, cancer diagnosis, cancer patient, clinical evaluation, cohort analysis, conference abstract, controlled study, female, glycemic control, Hispanic, human, incidence, major clinical study, non insulin dependent diabetes mellitus, race difference, retrospective study, risk factor, triple negative breast cancer
Abstract
INTRODUCTION: We sought to investigate the relationship between glycemic control, race, and the incidence of triple-negative breast cancer (TNBC) among patients with type 2 diabetes (T2D). METHODS: A retrospective cohort study evaluating 1,416 patients with T2D diagnosed with breast cancer between 2015 and 2020 was conducted. Tumor subtype was categorized as either hormone receptor-positive (ER+, PR+, or both) or triple-negative (ER/PRand HER2/neu-). Based on Hgb A1c measured within 3 months of cancer diagnosis, patients were assigned to one of three categories: well-controlled (Hgb A1c less than 7.0), moderately controlled (Hgb A1c 7.0-9.4), or poorly controlled (Hgb A1c greater than or equal to 9.5) T2D. RESULTS: A significant increase in the percentage of non-Hispanic White patients with TNBC across the three levels of glycemic control was observed (P=.037). When racial comparisons of cancer subtype within categories of glycemic control were performed, a significant (P=.001) increase in the percentage of Black patients with TNBC compared with non-Hispanic White patients was only observed among those with well-controlled T2D. CONCLUSION: Although previous studies have shown that Black patients are 2 to 3 times more likely to develop TNBC than their non- Hispanic White counterparts, a statistically significant racial difference was only noted among our patients with well-controlled T2D. Thus, our data not only suggest that T2D may serve as a modifiable risk factor for the development of TNBC but also that the risk conferred by poor glycemic control may bear more significance for non-Hispanic White patients than Black patients.
Volume
139
Issue
SUPPL 1
First Page
93S
